Naratriptan Stada Hemofarm (Naratriptan)

Naratriptan belongs to the triptan class and is used to treat migraine-related pathways.

• Migraine attack: provides rapid relief of headache pain and associated symptoms.
• Migraine-associated nausea: helps reduce nausea that often accompanies an attack.
• Migraine photophobia and phonophobia: improves tolerance to light and sound during an episode.

• Naratriptan acts as a selective agonist at serotonin 5‑HT1B and 5‑HT1D receptors located on intracranial blood vessels and sensory trigeminal nerves. Activation of these receptors causes cranial vasoconstriction and inhibits the release of pro‑inflammatory neuropeptides, thereby aborting the migraine cascade and alleviating headache pain.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Dizziness: transient light‑headedness.
• Fatigue: feeling of tiredness after dosing.
• Dry mouth: reduced salivation.
• Paresthesia: tingling sensations in extremities.
• Somnolence: occasional sleepiness.

Serious or Rare Side Effects

• Chest pain or tightness: possible cardiac ischemia.
• Severe hypertension: sudden rise in blood pressure.
• Serotonin syndrome: agitation, hyperthermia, tremor when combined with serotonergic agents.
• Allergic reaction: rash, itching, swelling, or anaphylaxis.
• Ischemic stroke: rare cerebrovascular event.
• Arrhythmia: irregular heart rhythm.

Before using Naratriptan, consider the following precautions.

• Cardiovascular disease: avoid if you have coronary artery disease, angina, or history of myocardial infarction.
• Uncontrolled hypertension: do not use if blood pressure is not well managed.
• Concomitant serotonergic drugs: monitor for signs of serotonin syndrome when combined with SSRIs, SNRIs, or MAO inhibitors.
• Pregnancy: discuss risks with a healthcare professional; use only if benefits outweigh potential risks.
• Breastfeeding: consult a physician before use, as drug may pass into milk.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Naratriptan may interact with several drug classes.

Major Interactions (Avoid)

• MAO inhibitors: increased risk of serotonin syndrome.
• Other triptans or ergotamine derivatives: additive vasoconstrictive effects.
• SSRIs, SNRIs, or other serotonergic agents: heightened serotonin toxicity.
• Strong CYP1A2 inhibitors (e.g., fluvoxamine): may raise naratriptan plasma levels.
• Cardiovascular stimulants: potential for excessive vasoconstriction.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: may require blood pressure monitoring.
• Oral contraceptives: slight increase in migraine frequency in some users.
• CYP1A2 inducers (e.g., smoking, carbamazepine): may reduce efficacy.